How should I assess and manage a patient with relapsed nodular‑sclerosing Hodgkin lymphoma, confirmed by biopsy, who now has new FDG‑avid lymphadenopathy below the diaphragm on PET/CT after completing six cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy?

Relapsed Nodular Sclerosing Hodgkin Lymphoma: Assessment and Management

This patient with biopsy-confirmed relapsed Hodgkin lymphoma after completing 6 cycles of ABVD requires salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), which represents the standard of care for relapsed disease. 1

Immediate Assessment

Confirm Relapse Status

• Biopsy confirmation is complete – this is critical and already done
• Restaging with PET/CT is complete – showing new FDG-avid sub-diaphragmatic lymphadenopathy
• Obtain bone marrow biopsy to assess extent of disease
• Assess cardiac and pulmonary function before salvage therapy
• Check performance status and organ function for transplant eligibility

Risk Stratification

This patient falls into a high-risk category based on:

• Time to relapse (appears to be early relapse, occurring after completion of first-line therapy)
• New sites of disease below the diaphragm suggest progression
• The specific timing relative to treatment completion will determine if this is primary refractory disease (≤3 months post-treatment) or early relapse (3-12 months post-treatment) 2

Treatment Plan

Primary Strategy: Salvage Chemotherapy → HDCT/ASCT

The goal of salvage therapy is to achieve PET-negative status before proceeding to transplant 1. This is critical because achieving complete metabolic response before ASCT significantly improves outcomes.

Salvage Chemotherapy Options (choose one):

1. DHAP (dexamethasone/high-dose cytarabine/cisplatin) 1
2. ICE (ifosfamide/carboplatin/etoposide) 1
3. IGEV (ifosfamide/gemcitabine/vinorelbine) 1
4. Single-agent brentuximab vedotin may be sufficient in select patients 1

These regimens have Level II-III, Grade A evidence and serve dual purposes: tumor cytoreduction and stem cell mobilization.

Response Assessment After Salvage

• Perform PET/CT after salvage chemotherapy
• If PET-negative: proceed directly to HDCT/ASCT
• If single PET-positive lymph node remains: consider involved-site radiotherapy before HDCT/ASCT 1
• If multiple PET-positive sites persist: consider additional salvage cycles or alternative agents

High-Dose Chemotherapy and ASCT

Once PET-negative status is achieved, proceed immediately to HDCT/ASCT 1. This is Level I, Grade A evidence as the treatment of choice for relapsed/refractory Hodgkin lymphoma.

Post-Transplant Consolidation

Brentuximab vedotin consolidation for 1 year following HDCT/ASCT is recommended given this patient's poor-risk features 1. This is Level II, Grade B evidence and has been shown to improve tumor control in patients with:

• Primary refractory disease
• Early relapse (<12 months)
• Extranodal disease at relapse

This patient likely meets at least one of these criteria based on the new sub-diaphragmatic involvement.

Alternative Considerations

If Patient is NOT Transplant-Eligible

• Single-agent brentuximab vedotin 1
• Consider clinical trial enrollment
• Palliative chemotherapy with gemcitabine-based regimens 1

If Disease Progresses After ASCT

Sequential options include:

1. Brentuximab vedotin (if not used as consolidation) 1
2. Anti-PD-1 antibodies (nivolumab or pembrolizumab) – FDA/EMA approved for patients who relapse after ASCT and brentuximab vedotin 1
3. Allogeneic stem cell transplantation – potentially curative option for young, chemosensitive patients in good condition 1

Critical Pitfalls to Avoid

1. Do not delay salvage therapy – early initiation improves transplant outcomes
2. Do not proceed to ASCT with PET-positive disease – achieving metabolic complete response is essential for optimal outcomes 1
3. Do not omit brentuximab vedotin consolidation in high-risk patients – this significantly improves progression-free survival 1
4. Do not use BEACOPP regimens if patient is >60 years old 1
5. Ensure adequate stem cell collection during salvage therapy before proceeding to transplant

Monitoring During Treatment

• CBC monitoring for myelosuppression during salvage therapy
• Cardiac monitoring given prior doxorubicin exposure
• PET/CT after salvage to guide transplant decision
• Post-ASCT surveillance with regular clinical assessment and imaging as indicated

The evidence strongly supports this aggressive approach in relapsed Hodgkin lymphoma, with HDCT/ASCT offering the best chance for long-term disease control and potential cure 1.